FindTrial
Sign In

We are comparing the effectiveness of homoeopathic medicine(THIOSINAMINUM) and Individualized homoeopathic medicines in the treatment of overgrowth of skin after injury,wound,burn etc

SYNOPSIS ON COMPARATIVE EFFECTIVENESS OF INDIVIDUALIZED HOMOEOPATHIC MEDICINES WITH THIOSINAMINUM IN CASES OF HYPERTROPHIC SCAR AND KELOID: AN OPEN-LABEL RANDOMIZED PRAGMATIC CLINICAL TRIAL - Interventional

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044287
Enrollment
50
Registered
2022-07-25
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L919- Hypertrophic disorder of the skin,unspecified Health Condition 2: L919- Hypertrophic disorder of the skin,unspecified

Interventions

Intervention1: INDIVIDUALIZED HOMOEOPATHIC MEDICINES: It is planned as administering indicated homoeopathic medicines centesimal potencies, as decided appropriate to the case or condition. In centesim
dosage and repetition depending upon the individual requirement of the cases. All medicines will be procured from a Good Manufacturing Practice(GMP)-certified firm .Duration of therapy: 6months Contro
dosage and repetition depending upon the individual requirement of the cases All medicines will be procured from a Good Manufacturing Practice (GMP)-certified firm. Duration of therapy: 6 months.

Sponsors

NATIONAL INSTITUTE OF HOMOEOPATHY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.The study population consisted of clinically diagnosed hypertrophic scars and keloids patient. 2.Age 5-60 years. 3.Symptomatic for at least last 6 months. 4.Patients with known but controlled systemic diseases with medication. 5.Patient giving written consent to participate.

Exclusion criteria

Exclusion criteria: 1.Unevaluated skin overgrowth abnormalities. 2.Patient with infected scars. 3.Patients with non-healing ulceration. 4.Patients suffering marjolinâ??s ulcer 5.Patients with psychiatric diseases. 6.Pregnancy and lactation. 7.Cases suffering from uncontrolled systemic illness or life-threatening infections or any vital organ failure. 8.Cases already undergoing homoeopathic treatment for any chronic purpose.

Design outcomes

Primary

MeasureTime frame
To compare the changes in POSAS and VSS scores between the two groups ,individualized homoeopathic medicines with empirically selected medicine THIOSINAMINUM.Timepoint: Baseline and after 6 months.—

Secondary

MeasureTime frame
To compare the changes in photograph findings between the two groups, individualized homoeopathic medicines with empirically selected medicine THIOSINAMINUM.Timepoint: Baseline and after 6 months.—

Countries

India

Contacts

Public ContactDR PRASANTA RATH

NATIONAL INSTITUTE OF HOMOEOPATHY

drprasantarath09@gmail.com8420924836

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026